TGA approves one-dose Kozenis for children with P. vivax malaria

March 14, 2022:

Medicines for Malaria Venture (MMV) The Australian Therapeutic Goods Administration (TGA) has announced the use of a single-dose Kozenis (tafenoquine) in children aged two years and older in combination with chloroquine for radical treatment (prevention of recurrence.) of Plasmodium vivax (P. vivax) malaria.

Admittedly a novel, 50 mg dispersible tablet that can be dispersed in water and developed by GSK in conjunction with MMV to train its use in children, who are affected by do not.

“We are proud to be working with GSK to develop this pediatric medicine and we are thrilled to announce today. P. vivax infection is a very serious infection in young children that can lead to severe anemia and, in some cases, even death. Today, we have a tool to end constant returns for banks and children – one area we are close to overcoming this disease. said Dr David Reddy, Chief Executive Officer, MMV.

Dr Thomas Breuer, Chief Health Officer, GSK, said, “We are pleased with Kozenis’s approval for pediatric populations. This initiative is a testament to the dedication of GSK scientists and our partner MMV, those who have not completed P. vivax prevention work over the age of 60 can be among the most vulnerable in the community, our children.

The submission was supported by a Phase 2b clinical study (TEACH) that evaluated dosages of tafenoquine based on the weight of children between two years of age, and weight in the range of 10 kg, up to 15 years.

Kozenis is a single drug to prevent recurrence of P. vivax and has been approved for people 16 years of age and older by the TGA in 2018. It should be used with a chloroquine supplement to treat in severe hemorrhagic fever, then the availability of medication.

The current state of treatment to prevent recurrence of P. vivax requires a course of 7 to 14 days of treatment with a drug called primaquine. Model of pediatric children purchased.

Further clinical trials are planned in malaria endemic countries for pediatric indications for tafenoquine. ET HealthWorld